Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Gross Profit: 2013-2025

Historic Gross Profit for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $20.0 million.

  • Theravance Biopharma's Gross Profit rose 18.51% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 27.12%. This contributed to the annual value of $64.4 million for FY2024, which is 12.12% up from last year.
  • As of Q3 2025, Theravance Biopharma's Gross Profit stood at $20.0 million, which was down 23.69% from $26.2 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Gross Profit high stood at $26.2 million for Q2 2025, and its period low was $2.5 million during Q1 2022.
  • In the last 3 years, Theravance Biopharma's Gross Profit had a median value of $15.7 million in 2023 and averaged $16.7 million.
  • As far as peak fluctuations go, Theravance Biopharma's Gross Profit surged by 850.47% in 2021, and later plummeted by 82.46% in 2022.
  • Theravance Biopharma's Gross Profit (Quarterly) stood at $14.9 million in 2021, then fell by 1.99% to $14.6 million in 2022, then rose by 19.91% to $17.6 million in 2023, then increased by 6.77% to $18.8 million in 2024, then increased by 18.51% to $20.0 million in 2025.
  • Its Gross Profit was $20.0 million in Q3 2025, compared to $26.2 million in Q2 2025 and $15.4 million in Q1 2025.